GLPBio

IRAK

Interleukin receptor-associated kinase (IRAK) is a family of serine/threonine-protein kinase that plays a vital role in innate immune immunity. It is involved in the TLR and IL-1R signaling pathways which associated with the autoimmune and inflammatory diseases.

Products Related to IRAK(36)

  • GC11103 structure
    GC11103IRAK inhibitor 3
    CAS: 1012343-93-9
    Purity: >98.00%
  • GC12651 structure
    GC12651IRAK inhibitor 2
    CAS: 928333-30-6
    Purity: >98.50%
  • GC15999 structure
    GC15999IRAK-1-4 Inhibitor I
    CAS: 509093-47-4
    Purity: >99.50%

    A benzimidazole

  • GC16264 structure
    GC16264IRAK inhibitor 4
    CAS: 1012104-68-5
    Purity: >98%
  • GC17158 structure
    GC17158IRAK inhibitor 1
    CAS: 1042224-63-4
    Purity: >99.00%

    An IRAK4 inhibitor

  • GC17371 structure
    GC17371IRAK inhibitor 6
    CAS: 1042672-97-8
    Purity: >99.50%

    An IRAK4 inhibitor

  • GC19287 structure
    GC19287PF06650833
    CAS: 1817626-54-2
    Purity: >98.00%

    PF06650833 (PF-06650833) is a potent, selective and orally active inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4) with IC50s of 0.2 and 2.4 nM in the cell and PBMC assay, respectively.

  • GC20007 structure
    GC20007Ginsenoside CK
    CAS: 39262-14-1
    Purity: >98.00%

    Ginsenoside CK, a secondary ginsenoside biotransformed from major ginsenosides, is more bioavailable and soluble than its parent ginsenosides and holds great significance.

  • GC31688 structure
    GC31688IRAK4-IN-1
    CAS: 1820787-94-7
    Purity: >99.00%

    IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC50 of 7 nM.

  • GC32748 structure
    GC32748CA-4948
    CAS: 1801343-74-7
    Purity: >99.50%

    CA-4948 is a selective, potent and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, extracted from patent WO2015104688 (example 1).

  • GC33054 structure
    GC33054AZ1495
    CAS: 2196204-23-4
    Purity: >99.50%

    AZ1495 is a novel, orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor.

  • GC36328 structure
    GC36328IRAK inhibitor 4 trans
    Purity: >99.00%

    IRAK inhibitor 4 (trans) is the trans form of IRAK inhibitor 4.

  • GC38799 structure
    GC38799IRAK4-IN-4
    CAS: 1850276-58-2
    Purity: >99.50%

    IRAK4-IN-4 is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor extracted from patent CN107163044A, Compound15, has an IC50 of 2.8 nM.

  • GC46013 structure
    GC46013AS-2444697 (hydrochloride)
    CAS: 1287665-60-4
    Purity: >95.00%

    AS-2444697 (hydrochloride) is an orally active IRAK-4 inhibitor with an IC50 of 21 nM.

  • GC61944 structure
    GC61944IRAK4-IN-6
    CAS: 2454244-02-9
    Purity: >99.50%

    IRAK4-IN-6 is an orally efficacious and selective IRAK4 inhibitor with an IC50 of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphoma.

  • GC62197 structure
    GC62197PROTAC IRAK4 degrader-1
    CAS: 2360533-90-8
    Purity: >99.50%

    PROTAC IRAK4 degrader-1 is a Cereblon-based PROTAC interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1 Compound I-210, makes 20-50%, and >50% IRAK4 degradation at 0.01, 0.1, and 1 μM in OCI-LY-10 cells, respectively.

  • GC62429 structure
    GC62429HS271
    CAS: 2410393-15-4
    Purity: >99.50%

    HS271 is a highly potent, orally active and selective IRAK4 inhibitor, with an IC50 of 7.2 μM.

  • GC62583 structure
    GC62583IRAK-4 protein kinase inhibitor 2
    CAS: 301675-24-1
    Purity: >99.00%

    IRAK-4 protein kinase inhibitor 2 (compound 1) is a potent inhibitor of interleukin-1 (IL-1) receptor-associated kinase-4 (IRAK-4), with an IC50 of 4 μM.

  • GC63263 structure
    GC63263Zabedosertib
    CAS: 1931994-81-8
    Purity: >99.00%

    Zabedosertib (BAY 1834845) is a IRAK4 inhibitor with immunomodulatory potential.

  • GC63925 structure
    GC63925JH-X-119-01
    CAS: 2227368-54-7
    Purity: >98.00%

    JH-X-119-01 is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor.

  • GC65941 structure
    GC65941HS-276
    CAS: 2767422-72-8
    Purity: >98.00%

    HS-276 is an orally active, potent and highly selective TAK1 inhibitor, with a Ki of 2.5 nM. HS-276 shows significant inhibition of TAK1, CLK2, GCK, ULK2, MAP4K5, IRAK1, NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC50 values of 8.25, 29, 33, 63, 125, 264, 270, 810, 1280, and 5585 nM, respectively. HS-276 can be used for rheumatoid arthritis (RA) research.

  • GC67879 structure
    GC67879Edecesertib
    CAS: 2408839-73-4
    Purity: >98%
  • GC68458 structure
    GC68458HS-243
    CAS: 848249-10-5
    Purity: >98%
  • GC69288 structure
    GC69288IRAK4-IN-21
    CAS: 2170694-04-7
    Purity: >99.00%

    IRAK4-IN-21 (Compound 17) is an orally effective and selective potent IRAK4 inhibitor with IC50 values of 5 and 56 nM for IRAK4 and TAK1, respectively. It can effectively inhibit the production of IL-23 (IC50=0.17 μM) and may be used in research on autoimmune diseases such as psoriasis vulgaris and psoriatic arthritis.